Comparison of Homology Medicines Inc. (FIXX) and UroGen Pharma Ltd.

Homology Medicines Inc. (NASDAQ:FIXX) and UroGen Pharma Ltd. (NASDAQ:URGN) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation. Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities?gene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.